|
Degenerative polyarthritis
|
0.320 |
Biomarker
|
disease |
BEFREE |
Deletion of developmental endothelial locus-1 (Del1) has been shown to increase severity of OA in knockout mice.
|
30278915 |
2018 |
|
Degenerative polyarthritis
|
0.320 |
Biomarker
|
disease |
BEFREE |
Del1 Knockout Mice Developed More Severe Osteoarthritis Associated with Increased Susceptibility of Chondrocytes to Apoptosis.
|
27505251 |
2016 |
|
Degenerative polyarthritis
|
0.320 |
Biomarker
|
disease |
CTD_human |
Mitochondrial dysregulation of osteoarthritic human articular chondrocytes analyzed by proteomics: a decrease in mitochondrial superoxide dismutase points to a redox imbalance.
|
18784066 |
2009 |
|
Osteoarthrosis Deformans
|
0.300 |
Biomarker
|
disease |
CTD_human |
Mitochondrial dysregulation of osteoarthritic human articular chondrocytes analyzed by proteomics: a decrease in mitochondrial superoxide dismutase points to a redox imbalance.
|
18784066 |
2009 |
|
Anxiety Disorders
|
0.100 |
GeneticVariation
|
group |
GWASCAT |
Genetic Variants Associated With Anxiety and Stress-Related Disorders: A Genome-Wide Association Study and Mouse-Model Study.
|
31116379 |
2019 |
|
Neoplasms
|
0.090 |
AlteredExpression
|
group |
BEFREE |
Del-1 expression in recurrent TAM-R breast cancer tissue was evaluated and compared to that in the original tumor tissue from the same patients.
|
31330520 |
2019 |
|
Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
Moreover, in accordance with previous studies, our data showed that tumor derived EDIL3 was involved in tumor associated bone loss.
|
31110935 |
2019 |
|
Neoplasms
|
0.090 |
AlteredExpression
|
group |
BEFREE |
Differences in expression between degrees of tumor differentiation suggest the potential of using changes in EDIL3 level as a new complementary diagnostic marker and target for anti-angiogenic therapy.
|
30961491 |
2019 |
|
Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
Knockdown of EDIL3 showed no significant influence on cell viability, migration, invasion and starvation-induced apoptosis, but compromised anoikis resistance and anchorage independent tumor growth of PDAC cells.
|
26735172 |
2016 |
|
Neoplasms
|
0.090 |
AlteredExpression
|
group |
BEFREE |
High level of EDIL3 protein is much more commonly in patients with larger tumor or portal vein tumor thrombus (PVTT) formation, associated with poor prognosis.
|
25273699 |
2014 |
|
Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
Histochemical staining revealed that E3-induced apoptosis in a tumour explant.
|
22782704 |
2013 |
|
Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
Although further investigation to clarify the mechanisms explaining the role of Del1 in tumor growth, and the interaction between VEGF and Del1, is required, the results indicate that downregulation of Del1 presents a potent therapeutic strategy to combat colon cancer.
|
19292890 |
2009 |
|
Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
Integrin alpha5beta1 is poorly expressed on normal quiescent blood vessels, but its expression is induced on tumor blood vessels and in response to angiogenic factors such as basic fibroblast growth factor, interleukin-8, tumor necrosis factor-alpha, and the angiomatrix protein Del-1.
|
14610084 |
2004 |
|
Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
Two clonal chromosome abnormalities were recurrent: interstitial 3p deletions were found in 5 carcinomas, whereas del(1)(q42) was detected in another 2 tumors.
|
8631024 |
1996 |
|
Tumor Progression
|
0.070 |
AlteredExpression
|
phenotype |
BEFREE |
TAM-R breast cancer is characterized by Del-1 overexpression and tumor progression can be inhibited by Del-1 depletion, which restores TAM sensitivity.
|
31330520 |
2019 |
|
Tumor Progression
|
0.070 |
Biomarker
|
phenotype |
BEFREE |
It is concluded that miR-137 regulates Del-1 expression in TNBC by directly binding to the <i>Del-1</i> gene and cancer progression.
|
31817673 |
2019 |
|
Tumor Progression
|
0.070 |
AlteredExpression
|
phenotype |
BEFREE |
Furthermore, a correlation was found between Del-1 expression and an aggressive histological grade, nuclear mitosis, and polymorphism, suggesting a possible role in tumor progression.
|
29393238 |
2018 |
|
Tumor Progression
|
0.070 |
Biomarker
|
phenotype |
BEFREE |
EDIL3 is significantly correlated with mesenchymal phenotype, angiogenesis, and tumor progression in lung adenocarcinoma.
|
28819306 |
2017 |
|
Tumor Progression
|
0.070 |
AlteredExpression
|
phenotype |
BEFREE |
Epidermal Growth Factor-like repeats and Discoidin I-Like Domains 3 (EDIL3), an extracellular matrix (ECM) protein associated with vascular morphogenesis and remodeling, is commonly upregulated in multiple types of human cancers and correlates with tumor progression.
|
26735172 |
2016 |
|
Tumor Progression
|
0.070 |
Biomarker
|
phenotype |
BEFREE |
Our findings demonstrated for the first time that there are deleterious effects of high levels of Del-1 in lung carcinoma cells, and suggest that Del-1 may be used as a diagnostic or prognostic marker for cancer progression, and as a novel therapeutic target for lung carcinoma.
|
26545781 |
2016 |
|
Tumor Progression
|
0.070 |
Biomarker
|
phenotype |
BEFREE |
Bladder cancer exosomes contain EDIL-3/Del1 and facilitate cancer progression.
|
24530986 |
2014 |
|
Malignant neoplasm of breast
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Del-1 expression in recurrent TAM-R breast cancer tissue was evaluated and compared to that in the original tumor tissue from the same patients.
|
31330520 |
2019 |
|
Malignant neoplasm of breast
|
0.040 |
Biomarker
|
disease |
BEFREE |
In this paper we explored the association between tumor derived EDIL3 and MDSCs in a murine breast cancer model.
|
31110935 |
2019 |
|
Breast Carcinoma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Del-1 expression in recurrent TAM-R breast cancer tissue was evaluated and compared to that in the original tumor tissue from the same patients.
|
31330520 |
2019 |
|
Breast Carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
In this paper we explored the association between tumor derived EDIL3 and MDSCs in a murine breast cancer model.
|
31110935 |
2019 |